Filtered By:
Condition: Atrial Fibrillation
Cancer: Cancer

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 359 results found since Jan 2013.

Atrial fibrillation in cancer: thromboembolism and bleeding in daily practice
CONCLUSION: Patients with AF and active cancer experience high rates of thromboembolic and bleeding complications, underlying the complexity of anticoagulant management in these patients. Our data suggest that the presence of cancer is an important factor in determining the indication for anticoagulants in patients with a low CHA2DS2-VASc score.PMID:37063771 | PMC:PMC10099322 | DOI:10.1016/j.rpth.2023.100096
Source: Thrombosis and Haemostasis - April 17, 2023 Category: Hematology Authors: Gordon Chu Jaap Seelig Suzanne C Cannegieter Hans Gelderblom Marcel M C Hovens Menno V Huisman Tom van der Hulle Serge A Trines Andr é J Vlot Henri H Versteeg Martin E W Hemels Frederikus A Klok Source Type: research

Altered plasma levels of apixaban in major gastrointestinal tract surgery: a case report and review of the literature
We describe a case of suspected altered apixaban disposition in a patient with an upper gastrointestinal cancer resection treated with apixaban for non-valvular atrial fibrillation. Diagnosis of ischemic stroke for left hemiparesis was confirmed due to recent emergence of a hypodense area in the posterior capsular nucleus of ischemic reference in a context of binuclear capsular lacunar lesions. Thus, apixaban underexposure was suspected from anamnestic data and oral anticoagulation was switched to parenteral at the next scheduled dose for stroke recurrence. Before switching apixaban pharmacokinetic analysis was performed a...
Source: Clinical Biochemistry - July 14, 2023 Category: Biochemistry Authors: Giammarco Baiardi Alessia Cafaro Manuela Stella Michela Cameran Caviglia Maria Gabriella Poeta Giuliana Cangemi Francesca Mattioli Source Type: research

Altered plasma levels of apixaban in major gastrointestinal tract surgery: A case report and review of the literature
We describe a case of suspected altered apixaban disposition in a patient with an upper gastrointestinal cancer resection treated with apixaban for non-valvular atrial fibrillation. Diagnosis of ischemic stroke for left hemiparesis was confirmed due to recent emergence of a hypodense area in the posterior capsular nucleus of ischemic reference in a context of binuclear capsular lacunar lesions. Thus, apixaban underexposure was suspected from anamnestic data and oral anticoagulation was switched to parenteral at the next scheduled dose for stroke recurrence. Before switching apixaban pharmacokinetic analysis was performed a...
Source: Clinical Biochemistry - July 14, 2023 Category: Biochemistry Authors: Giammarco Baiardi Alessia Cafaro Manuela Stella Michela Cameran Caviglia Maria Gabriella Poeta Giuliana Cangemi Francesca Mattioli Source Type: research

Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Abstract The target-specific oral anticoagulants are a class of agents that inhibit factor Xa or thrombin. They are effective and safe compared to warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation and for the treatment of venous thromboembolism, and they are comparable to low-molecular-weight heparin for thromboprophylaxis after hip or knee arthroplasty. For other indications, however, such as the prevention of stroke in patients with mechanical heart valves, initial studies have been unfavorable for the newer agents, leaving warfarin the anticoagulant of choice. Furt...
Source: Annual Review of Medicine - January 14, 2015 Category: Journals (General) Authors: Arepally GM, Ortel TL Tags: Annu Rev Med Source Type: research

Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study
Conclusion: Medical and social variables were associated with prescription of NOAC. Major bleeding, hemorrhagic stroke, university education, and higher glomerular filtration rate were more frequent among patients under NOAC. On the contrary, patients with history of cancer or bradyarrhythmias more frequently received VKA.
Source: Journal of Cardiovascular Pharmacology and Therapeutics - February 24, 2016 Category: Cardiology Authors: Moreno-Arribas, J., Bertomeu-Gonzalez, V., Anguita-Sanchez, M., Cequier, A., Muniz, J., Castillo, J., Sanchis, J., Roldan, I., Marin, F., Bertomeu-Martinez, V., on behalf of the investigators of the FANTASIIA study Tags: Clinical Studies Source Type: research

The emerging role of galectins in cardiovascular disease.
Abstract Galectins are an ancient family of β-galactoside-specific lectins and consist of 15 different types, each with a specific function. They play a role in the immune system, inflammation, wound healing and carcinogenesis. In particular the role of galectin in cancer is widely studied. Lately, the role of galectins in the development of cardiovascular disease has gained attention. Worldwide cardiovascular disease is still the leading cause of death. In ischemic heart disease, atherosclerosis limits adequate blood flow. Angiogenesis and arteriogenesis are highly important mechanisms relieving ischemia by rest...
Source: Vascular Pharmacology - March 2, 2016 Category: Drugs & Pharmacology Authors: van der Hoeven NW, Hollander MR, Yıldırım C, Jansen MF, Teunissen PF, Horrevoets AJ, van der Pouw Kraan TC, van Royen N Tags: Vascul Pharmacol Source Type: research

Endothelial Small- and Intermediate-Conductance K Channels and Endothelium-Dependent Hyperpolarization as Drug Targets in Cardiovascular Disease.
Abstract Endothelial calcium/calmodulin-gated K channels of small (KCa2.3) and intermediate conductance (KCa3.1) produce membrane hyperpolarization and endothelium-dependent hyperpolarization (EDH)-mediated vasodilation. Dysfunctions of the two channels and ensuing EDH impairments are found in several cardiovascular pathologies such as diabetes, atherosclerosis, postangioplastic neointima formation, but also inflammatory disease, cancer, and organ fibrosis. Moreover, KCa3.1 plays an important role in endothelial barrier dysfunction, edema formation in cardiac and pulmonary disease, and in ischemic stroke. Concerni...
Source: Advances in Pharmacology - July 29, 2016 Category: Drugs & Pharmacology Authors: Köhler R, Oliván-Viguera A, Wulff H Tags: Adv Pharmacol Source Type: research

AliveCor raises $30m, launches Kardia Pro platform in U.S.
AliveCor said today that it landed $30 million in a series D funding round and that it released its artificial intelligence-enabled Kardia Pro platform in the U.S. The company’s platform enables doctors to remotely monitor their patients for early signs of atrial fibrillation, a common cardiac arrhythmia. “Heart disease is the No. 1 cause of death in the United States, claiming more lives than all forms of cancer combined. To manage heart disease and stroke risk, leading cardiologists want to see more than just ECGs from their patients,” CEO Vic Gundotra said in prepared remarks. “Kardia Pro tracks important meas...
Source: Mass Device - March 16, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Cardiovascular Funding Roundup Patient Monitoring Wall Street Beat AliveCor Source Type: news

Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality – a systematic review and dose-response meta-analysis of prospective studies
Conclusion This meta-analysis found an increased risk of coronary heart disease, sudden cardiac death, heart failure, atrial fibrillation, stroke, cardiovascular disease, total cancer and all-cause mortality with greater resting heart rate.
Source: Nutrition, Metabolism and Cardiovascular Diseases - April 22, 2017 Category: Nutrition Source Type: research

Insights on mid-term TAVR performance: 3-year clinical and echocardiographic results from the CoreValve ADVANCE study
ConclusionsOur 3-year data demonstrate significant hemodynamic benefits and durable symptom relief after CoreValve prosthesis implantation. Postprocedural patient management should be carefully considered, since postprocedural valve-related events were identified as independent predictors of mid-term mortality.Trial registration ClinicalTrials.gov, NCT01074658.
Source: Clinical Research in Cardiology - May 8, 2017 Category: Cardiology Source Type: research

Causes of death in atrial fibrillation: Challenges and opportunities
Atrial fibrillation (AF) is an age-related arrhythmia associated with several co-morbidities and significant mortality. Most AF patients are in need of anticoagulation due to increased risk of stroke. Despite anticoagulation, AF patients still have a significant risk of death (about 5% per year). Approximately half of deaths in AF are due to heart-related causes (i.e.: sudden death, heart failure, myocardial infarction), one third of deaths are due to non-vascular causes (i.e.: cancer, respiratory diseases, infections, etc) and the remaining AF patients die from stroke or hemorrhage (about 6% each), or other causes.
Source: Trends in Cardiovascular Medicine - May 10, 2017 Category: Cardiology Authors: Antonio G ómez-Outes, Ma Luisa Suárez-Gea, Jose Manuel García-Pinilla Source Type: research